Genprex

News

2 Austin medical companies expect to raise millions with stock offerings

Two Austin-based companies involved in medial research say they expect to raise millions of dollars with stock offerings this week.

Read More

Genprex, Inc. Announces $25 Million Registered Direct Offering Priced At-The-Market Under NASDAQ Rules, Without Warrants

Genprex has entered into securities purchase agreements with two healthcare-dedicated institutional investors for the purchase and sale of 4,000,000 shares of its common stock at a purchase price of $6.25 per share in a registered direct offering priced at-the-market under Nasdaq rules.

Read More

Genprex Announces Formation of Clinical Advisory Board

World reknowned medical and clinical experts to guide Genprex’ novel gene therapy clinical development programs in cancer and diabetes, including its two upcoming clinical trials in lung cancer

Read More

Genprex Recognizes World Cancer Day

Joins Global Movement to Raise Awareness and Reduce the Burden of Cancer Worldwide

Read More

Genprex is on the Cutting Edge of Lung Cancer Treatment Development

Mr. Redman provides his reaction to a recent article in ONCOLOGY® and discusses how Genprex is harnessing breakthroughs in lung cancer treatment.

Read More

Genprex Issues Shareholder Letter and Provides Corporate Update

Major milestones achieved in advancing gene therapies for lung cancer and diabetes

Read More

Genprex to Present at the Virtual Investor Conference Small and Microcap Showcase on February 4

Company to provide update on upcoming clinical trials for the treatment of non-small cell lung cancer and an overview of its diabetes gene therapy

Read More

Genprex to Present its Cutting-Edge Gene Therapies at the MoneyShow Accredited Investors Virtual Expo

Presentation to Highlight Company’s Recent Advancements on its Upcoming Clinical Trials for the Treatment of Non-Small Cell Lung Cancer

Read More

Genprex to Present at NobleCon17 on January 19

Presentation to Highlight the Company’s Recent Progress on its Upcoming Clinical Trials for the Treatment of Non-Small Cell Lung Cancer

Read More

Genprex Achieves Major Manufacturing Milestone for REQORSA™ Immunogene Therapy for Upcoming Trials to Treat Non-Small Cell Lung Cancer

Company passes final release tests of scaled-up clinical grade production to supply drug product for upcoming Acclaim-1 and Acclaim-2 clinical trials in lung cancer

Read More